4,5- dihydro- 6- (4- (imidazol- 1- yl)phenyl)- 5- methyl- 3(2H)- pyridazinone

06/01/1987 - "These findings suggest that intravenous CI-930 hydrochloride is a useful therapeutic agent in congestive heart failure and that its use does not appear to further activate potentially deleterious hormonal systems."
06/01/1987 - "The acute hemodynamic and hormonal effects of intravenous CI-930 were studied in 9 patients with severe congestive heart failure. "
05/01/1987 - "Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy."
06/01/1987 - "Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure."
05/01/1987 - "CI-930, a new type III phosphodiesterase inhibitor, was evaluated for treatment of refractory congestive heart failure. "

07/01/1991 - "CI-930 0.625 and 2.5 mg.kg-1 i.v. exhibited a dose-dependent inhibitory effect on thrombus formation in rat arteriovenous shunt. "
07/01/1991 - "Effects of CI-930 on hemostasis, thrombosis, and AA-induced hemodynamic reaction."

11/01/1995 - "Rolipram, CI-930, aminophylline and dexamethasone (at maximum doses for inhibiting pulmonary edema) inhibited the 3-fold increase in bronchoalveolar lavage albumin concentration 24 hr after LPS exposure (42 +/- 14%, 98 +/- 2%, 70 +/- 9% and 53 +/- 13%, respectively). "
11/01/1995 - "Denbufylline and milrinone also inhibited pulmonary edema formation at 10 mg/kg i.p., supporting the inhibition of PDE4 and PDE3 as the mechanisms of action of rolipram and CI-930, respectively. "

05/01/1987 - "Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy."